Research
AI-discovered drug rentosertib enters Phase III trial
Rentosertib, an AI-discovered TNIK inhibitor for IPF, enters Phase III with 320 patients. It is the first fully AI-originated drug to reach late-stage trials.
#pharma.ai
1 story tagged pharma.ai.